FINWIRES · TerminalLIVE
FINWIRES

Ola Electric Mobility Raises INR7.8 Billion Through QIP

By

Ola Electric Mobility (NSE:OLAELEC, BOM:544225) has raised around 7.80 billion Indian rupees through a qualified institutions placement (QIP), according to a Thursday filing to the Indian stock exchanges.

The electric vehicles manufacturer allotted around 217.6 million equity shares of face value of 10 rupees each to eligible qualified institutional buyers at an issue price of 35.86 rupees per equity share, including a premium of 25.86 rupees.

The company said the issue opened on June 1 and closed on June 4.

Following the allotment of shares, the paid-up equity share capital of the company has increased to 46.3 billion rupees, comprising 4.63 billion equity shares of face value of 10 rupees each, from 44.1 billion rupees, comprising 4.41 billion equity shares of face value of 10 rupees each.

Related Articles

Asia

Lendlease Global Commercial REIT Redeems Perpetual Securities Worth SG$200 Million

Lendlease Global Commercial REIT (SGX:JYEU) has fully redeemed SG$200 million worth of 4.20% subordinated perpetual securities on Thursday, June 4, according to a same-day filing with the Singapore Exchange.The securities will now be canceled and delisted from the Singapore Exchange, the filing added.

$SGX:JYEU
Asia

Market Chatter: Singapore Airlines in Discussions with Airbus, Boeing for New Jet Order

Singapore Airlines (SGX:C6L) is in negotiations with Airbus and Boeing to purchase at least 50 large wide-body jets, Reuters reported on Thursday, citing two industry sources.The airline company is seeking offers for either a Boeing 777X model or an Airbus A350-1000, with negotiations still at an early stage, the report said.This comes after the company had outlined its intention to continue expanding its capacity, despite competitors pulling back, the report added.The new orders are expected to help the company in the next phase of its growth, the report said.Singapore Airlines was cited in the report as saying that fleet renewal is being reviewed regularly, but refused to comment on "any confidential discussions that we may or may not be having." Meanwhile, both Boeing and Airbus declined to comment, Reuters said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$SGX:C6L
Asia

Sichuan Biokin Pharmaceutical Secures China Clinical Trial Approval for Lymphoma Injection

China's drug regulator approved Sichuan Biokin Pharmaceutical's (SHA:688506) clinical trial for its BL-M08D1 injection as a combination therapy for diffuse large B-cell lymphoma, according to a Friday filing with the Shanghai bourse.Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, according to the Mayo Clinic.BL-M08D1 is also undergoing phase 1B trials for relapsed or refractory hematologic malignancies and locally advanced tumors.

$SHA:688506